The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s demonstrating significant potential in clinical trials for treating obesity. Unlike some existing weight loss approaches, retatrutide appears to offer a more substanti